Skip to main content
SpringerLink
Log in

Rationale for the Prevention of Disseminated Mycobacterium avium-intracellulare Complex Disease

  • Published:
Drugs Aims and scope Submit manuscript

Summary

The survival rate in patients with AIDS who have CD4+ cell counts < 75 cells/μl is increasing because of improved preventive and treatment strategies for opportunistic infections and also because of the efficacy of antiretroviral drug treatment. These patients are at high risk of developing disseminated Mycobacterium avium-intracellulare (MAC) disease, which decreases both quality of life and life expectancy.

Measures aimed at preventing MAC contamination are largely ineffective in decreasing the incidence of disseminated MAC disease in patients with AIDS, because of the large natural reservoir of MAC. Chemoprophylaxis is superior to early bacteriological diagnosis as a preventive strategy, and it is preferable to wait for the appearance of symptoms of disseminated MAC disease before a curative treatment is initiated. Well-conducted studies of clarithromycin or rifabutin monotherapy as chemoprophylaxis have demonstrated a decrease in the incidence of disseminated MAC disease, as well as an increase in quality of life and survival.

Clarithromycin, azithromycin and rifabutin have all been shown to be effective as prophylaxis against disseminated MAC disease. Although some combinations of drugs have been shown to be more effective than monotherapy in preventing disseminated MAC disease, these regimens are more costly and have less favourable tolerability profiles than single-agent treatment.

In conclusion, chemoprophylaxis is the most effective preventive strategy against disseminated MAC disease and has been shown to improve quality of life and to decrease the risk of death associated with this disease in AIDS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of M. avium intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082–5

    Article  PubMed  CAS  Google Scholar 

  2. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic M. avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121:905–11

    PubMed  CAS  Google Scholar 

  3. Centers for Disease Control and Prevention (CDC). Recommendations on prophylaxis and therapy for disseminated M. avium complex for adults and adolescents infected with human immunodeficiency virus. Morb Mortal Wkly Rep 1993; 42: 14–20

    Google Scholar 

  4. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium complex. N Engl J Med 1993; 329: 898–904

    Article  PubMed  CAS  Google Scholar 

  5. Von Reyn CF, Maslow JN, Barber TW, et al. Persistent colonization of potable water as a source of M. avium infection in AIDS. Lancet 1994; 343: 1137–41

    Article  Google Scholar 

  6. Chin DP, Reingold AL, Stone EN, et al. The impact of M. avium complex bacteremia and its treatment on survival of AIDS patients — a prospective study. J Infect Dis 1994; 170: 578–84

    Article  PubMed  CAS  Google Scholar 

  7. Pierce M, Lamarca A, Jablonowski H, et al. A placebo-controlled trial of clarithromycin. In: Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7: Orlando (FL): ASM, 1994: Late Breaker A2

  8. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against M. avium infection in AIDS patients. Am Rev Respir Dis 1991; 144 (3 Part 1): 564–9

    Article  PubMed  CAS  Google Scholar 

  9. Young LS, Wiviott L, Wu M, et al. Azithromycin for treatment of M. avium-intracellulare complex infection in patients with AIDS. Lancet 1991; 338: 1107–8

    Article  PubMed  CAS  Google Scholar 

  10. Dautzenberg B, Castellani P, Truffot-Pernot Ch, et al. Early bactericidal effect of rifabutin monotherapy versus placebo for MAC bacteremia in AIDS patients. Antimicrob Agents Chemother 1996; 40: 1722–5

    PubMed  CAS  Google Scholar 

  11. Nightingale SA, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 29: 828–33

    Article  Google Scholar 

  12. Maslo C, Bure-Rossler A, Gholizdeh Y, et al. Rifabutin prophylaxis of Mycobacterium avium complex bacteremia in severely immunocompromised AIDS patients. 3rd Conference on Retroviruses and Opportunistic Infections. 1996 Jan 28–Feb 1: Washington DC

  13. Oldfield EC, Dickinson G, Chung R, et al. Once weekly azithromycin for the prevention of Mycobacterium avium complex (MAC) infection in AIDS patients [abstract 203]. 3rd Conference on Retroviruses and Opportunistic Infections. 1996 Jan 28–Feb 1: Washington, 90

  14. Pfizer Inc, New York, NY. Azithromycin MAC prophylaxis NDA H. 3: Clinical trials relevant to the claim structure and H. 4: Overall summary of efficacy. December 1995

  15. Ji B, Lounis N, Truffot-Pernot C, et al. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother 1992; 36: 2839–40

    Article  PubMed  CAS  Google Scholar 

  16. Chaisson AE, Keiser M, Pierce M, et al. Controlled trial of clarithromycin/ethambutol with or without clofazimine for treatment of Mycobacterium avium complex bacteremia in AIDS patients [abstract no. 164]. 3rd Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28–Feb 1: Washington

  17. Benson CA, Cohn DL, Williams P, et al. A Phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs. rifabutin (RBT) vs. CLA+ RBT for prevention of Mycobacterium avium complex (MAC) disease in HIV+ patients with CD4+ counts ≤ 100 cells/μL [abstract no. 205]. 3rd Conference on Retroviruses and Opportunistic Infections. 1996 Jan 28–Feb 1: Washington

  18. Havlir DV, Du Bel MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin or both. N Engl J Med 1996; 335: 392–8

    Article  PubMed  CAS  Google Scholar 

  19. Jacobs DS, Piliero PJ, Kuperwaser MG, et al. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol 1994; 118: 716–22

    PubMed  CAS  Google Scholar 

  20. The Indinavir (MK639) Pharmacokinetic Study Group. Indinovir (MK639) drug interaction studies [abstract no. POB 174]. XIth International Conference on AIDS: 1996 Jul 7–12: Vancouver

  21. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep 1996; 45: 921–5

    Google Scholar 

  22. Horsburgh CR. Advances in the prevention and treatment of Mycobacterium avium disease. N Engl J Med 1996; 335:428–9

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Pneumologie, Groupe Hospitalier Pitié-Salpêtrière, 75651, Paris, Cedex 13, France

    Bertrand Dautzenberg

Authors
  1. Bertrand Dautzenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dautzenberg, B. Rationale for the Prevention of Disseminated Mycobacterium avium-intracellulare Complex Disease. Drugs 54 (Suppl 2), 1–7 (1997). https://doi.org/10.2165/00003495-199700542-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199700542-00003

Keywords

Search

Navigation